Abstract
Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Current Pharmaceutical Design
Title: Lipid Management for the Prevention of Cardiovascular Disease
Volume: 17 Issue: 9
Author(s): Juergen R. Schaefer
Affiliation:
Keywords: Lipid lowering therapy, atherosclerosis, coronary artery disease, prevention, cardiology, diabetes mellitus, atherogenic, overwhelming, revascularisation,, Lipidhypothesis, hyperlipidemia, simvastatin, Myopathic, rhabdomyolysis, cyclosporine, macrolide, digoxin, rosuvastatin, Ezetimibe
Abstract: Lowering low density lipoprotein (LDL) - cholesterol is one of the key issues in modern preventive cardiology by which we are able to interact with the natural course of atherosclerosis. Diet and healthy life style are mandatory for the treatment of CAD high risk patients. Numerous lipid lowering trials confirmed the beneficial effect of statins in primary as well as secondary prevention. By this statins are the basic treatment in patients with coronary artery disease (CAD) or diabetes mellitus or both. In order to reach LDL - cholesterol target levels (LDL - cholesterol < 100 mg/dl) in patients with CAD the use of potent statins or a lipid lowering combination therapy might be necessary. In our days we are able to lower LDL-cholesterol by more than 50% with drug treatment, which should enable us to reach the optimal LDL-cholesterol level in most patients.
Export Options
About this article
Cite this article as:
R. Schaefer Juergen, Lipid Management for the Prevention of Cardiovascular Disease, Current Pharmaceutical Design 2011; 17 (9) . https://dx.doi.org/10.2174/138161211795428849
DOI https://dx.doi.org/10.2174/138161211795428849 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Getting to Know the Cast - Cellular Interactions and Signaling at the Neurovascular Unit
Current Pharmaceutical Design Postmenopausal Hormone Therapy
Current Women`s Health Reviews Molecular Mechanisms of Glucocorticoids Action: From Basic Research to Clinical Implications
Current Immunology Reviews (Discontinued) Severe Acute Respiratory Syndrome (SARS): A Brief Review With Exploration of the Outcomes, Prognostic Factors and Sequelae
Current Respiratory Medicine Reviews Non-transfusion Dependent Thalassemias: A Developing Country Perspective
Current Pediatric Reviews Synthesis, Docking and Antidiabetic Activity of Some Newer Benzamide Derivatives as Potential Glucokinase Activators
Letters in Drug Design & Discovery Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets The Clinical Utility of Ambulatory Blood Pressure Monitoring (ABPM): A Review
Current Hypertension Reviews Metal Catalyzed Oxidation of Alpha-Synuclein – A Role for Oligomerization in Pathology?
Current Alzheimer Research Neutrophil Gelatinase-Associated Lipocalin (NGAL) as a New Biomarker for Non – Acute Kidney Injury (AKI) Diseases
Inflammation & Allergy - Drug Targets (Discontinued) Antiplatelet and Anticoagulation Strategies in the Prevention and Treatment of Ischemic Stroke
Current Pharmaceutical Design Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors
Current HIV Research SIRT1 – An Anti-Inflammatory Pathway at the Crossroads Between Metabolic Disease and Atherosclerosis
Current Vascular Pharmacology Adiposity and Alzheimers Disease
Current Alzheimer Research Matrix Metalloproteinases and their Tissue Inhibitors in Diabetes, Atherosclerosis and Prediction of the Cardiovascular Risk
Current Enzyme Inhibition Saxagliptin: A New Drug for the Treatment of Type 2 Diabetes
Mini-Reviews in Medicinal Chemistry Recent Knowledge and New Pharmaceutical Products in Potential Alleviation of Endometriosis
Recent Patents on Inflammation & Allergy Drug Discovery Diabetes without Manifest Cardiovascular Disease: A Novel Approach in Risk Stratification and Treatment Selection
Current Diabetes Reviews Type 2 Diabetes Mellitus: New Genetic Insights will Lead to New Therapeutics
Current Genomics Dietary Fats and Oils in India
Current Diabetes Reviews